Apr
12

Part D enrollee satisfaction

The Washington Post published results of a study that indicate a generally modest level of satisfaction with Part D among enrollees. According to the Post, “Three-fourths of Medicare beneficiaries enrolled in the drug benefit say paperwork to sign up was easy to complete, and almost two-thirds say the program saves them money…”
I’d just point out that seniors are pretty sharp consumers, and the ones who signed up for Part D are likely those who did the math to figure out the cost-benefit.
This is called adverse selection, and is the main reason the program will not be successful over the long term. Simply put, the ones who sign up are the ones who will get more in benefits than they will pay in premiums.
Matt Holt’s Fierce Healthcare points out that the Post erred in stating that 29 million had signed up for Part D – this number actually included all seniors with some form of drug coverage from Medicaid, Medicare Advantage, or other sources, and grossly overstates the actual enrollment – which is about 30% of eligibles.
Also of note is this stat – among all seniors surveyed, (those with and without Part D coverage), 41% approve of the benefit and 45% don’t. Leaving aside the health policy issues of Part D, it sure does not look like a political win for the current Administration.


Apr
6

Survey of Prescription Drug Management in Workers Comp

My firm, Health Strategy Associates, is conducting the Third Annual Survey of Prescription Drug Management in Workers Comp, and I’m hoping to have the final report completed before the end of April. Here are a couple of interesting bits that have come up in the 20+ interviews conducted to date.
1. There is a rather striking difference in the pharmacy inflation rate between what I would characterize as less- and more-sophisticated payers. Some payers have held their inflation rates down in the lower single digits, others are seeing trend rates above 15%.
2. Claim frequency decreases get part of the credit for low pharmacy inflation, but not all of it.
3. The number of PBMs is growing, but no PBM has a dominant market position. In fact, many senior execs don’t know much about the PBMs beyond their names.
4. Cost inflation tends to be attributed to more “designer” drugs, e.g. more expensive branded drugs being prescribed when a cheaper generic would likely work; direct to consumer advertising’s impact on consumers, and more claimants getting more drugs for longer periods.
5. This last is probably the most consistent thread running throughout the interviews – a heightened awareness of and concern about the sheer volume of drugs prescribed.
I’ll post additional highlights when they make themselves apparent. If you want a copy of the survey report, email me at jpaduda@healthstrategyassoc.com.


Apr
5

Work comp drug talk round 2

For the dozen folks who find this remotely interesting – A few factoids and interesting tidbits from around the WC PBM world.
The legislative efforts in California to address repackagers and dispensing of drugs by physicians appears to be stalled, and may not progress this year. This is bad news for payers and policyholders, as repackaged drugs account for over 50% of drug costs in California and that number is heading up.
Third party billers pay pharmacies about what most PBMs do, thus the reason pharmacies send their scripts to TPBs is because it is less work.
Sources indicate about 2% of all workers comp scripts are never picked up. If the pharmacy billed the script through a PBM, it will be reversed and the PBM and payer credited. This does not appear to be happening with third party billers. Anyone out there ever had a third party biller come back to them and reverse a charge? Anyone???
One third party biller strategy being discussed by a major comp payer is to require the biller to verify that each script was picked up. This could be in the form of a photocopy of the signature log or attestation by an officer of the TPB.
A source’s billing and payment data indicate that many payers, including at least two of the top five national WC insurers, pay third party billers at or close to billed charges in states without fee schedules. Meanwhile, other payers are cutting those bills to AWP-10% +$3.00 and not getting much pushback.
Word has it that Kroger’s is getting paid at straight AWP by their third party biller…no wonder they are not contracting with any workers comp PBMs.
Meanwhile, Medco is forcing pharmacies to accept group health reimbursement for their (very few) workers comp clients. Workers comp does not appear to be anything more than an accomodation for a very few of Medco’s largest customers, as Medco does not actively sell into the comp sector. My sense is if Medco did have more WC business, they very likely would have a lot more pushback from the pharmacy chains.


Mar
29

Part D’s failure is good news for pharmacies

I noted a couple weeks ago the problems pharmacies in Texas have been encountering with Part D – slow pays, no pays, missing information, higher staffing costs, and the like. Now word comes that California pharmacies seem to be suffering the same side effects of Part D.
The news comes from the Sacramento Bee (free registration required), and was triggered by reports of a home-delivery pharmacy shutting its doors, at least in part due to payment problems associated with Part D. According to the Bee;
“In a CPA (California Pharmacy Association) survey about Medicare Part D, 55.8 percent of independent pharmacies said the drug program’s timing of payments has created a “significant negative financial impact” on their business.”
Ohio pharmacies, especially the independents, are also experiencing financial troubles they attribute largely to Part D. While many of these issues were recognized early this year, the financial impacts are only now really starting to be felt.
The independents don’t have large chains’ financial backing nor buying power; this will make it very difficult for those in anything less than excellent financial shape to survive while Part D is sorted out. As independents account for 43% of all pharmacies, this is no small issue.
The good news is few eligible seniors have signed up for Part D. This presents us with an interesting picture – the success of a program designed to get more drugs to more people may well have killed off many independent pharmacies.
Only in Washington could they have come up with something so creatively destructive.


Mar
27

Whither part D? or Wither Part D?

It’s not often the President of the United States does health benefit plan enrollment meetings, so Bush’s recent national tour touting Part D stands out as one of the more unique moments in health benefits history. But this is more than an interesting factoid, because Bush’s speaking tour came about because of the dismal enrollment rates seen to date. And with the enrollment period ending in less than two months, it does not look like things will get much better.
While the President touts the enrollment of 25 million seniors into the program so far, 20 million of those had coverage before the program started. That leaves a total of 23 million seniors eligible for enrollment – out of which 5 million, or less than 22% have taken the plunge.
As I’ve been saying all along, any voluntary benefits plan with participation under 70% is in trouble – so Part D looks to be in big trouble.
If enrollment stays slow and low, Congress may well have to extend the enrollment period. While Bush has said that is a non-starter, he also threatened to veto any Congressional action on the Dubai Ports deal. This turned out to be a hollow threat, and with Congress increasingly independent of the White House, and Republicans seeking to salvage anything from the ashes of Part D, an extension could well be in the works.
(Bob Laszewski was the first to characterize Bush’s role in enrollment meetings)


Mar
13

Pharmacists, Part D, and politics

The law of unintended consequences continues to dog the much-maligned Part D program. So far, seniors and states have been depicted as the primary victims of the program’s operational, structural, and marketing faults. Now there’s news that the program’s impact on pharmacists is resulting in political fallout for the White House.
The New York Times reported yesterday that a (free registration required) group of pharmacists from Texas met with White House political boss Karl Rove to voice concerns about Part D. While their complaints include the additional time required of pharmacists to explain the program to seniors and advise them on which of the myriad offerings works best for them, by far the more significant issue appears to be the financial fallout.
Pharmacies’ problems include slow payment by Part D vendors; lower reimbursement rates; extra labor costs incurred while (free registration required) pharmacists wrestled with administrative nightmares; and the cost of free scripts given away to seniors lost in the bureaucratic mess.
According to a pharmacist in California: “It’s really bad and it’s been a disaster for us…Our reimbursement rates have gone down. Medicare Part D has really hurt us.”
While the administrative and operational issues look to be solvable, the reimbursement issue will not go away. Pharmacists are discovering that in many cases their reimbursement under Part D is less than it was under Medicare, making Part D significantly less attractive. And that comes on top of a reduction in Medicaid drug dispensing fees that went into effect last year.
According to the pharmacists from Bush’s home state, these problems have combined to push many pharmacies, especially the mom-and-pops, to the financial brink. The result is these independent business people, many of which have been ardent supporters of the President, feel victimized by the program. Bush’s recent comment that “It’s not immoral to make sure that prescription drug pharmacists don’t overcharge the system” further alienated pharmacists.
The winners in Part D look to be big pharma, PBMs, managed care firms, and employers. In addition to taxpayers, seniors and pharmacies, losers may include the President and his allies on Part D.


Mar
10

Bush’s problems – HSAs, Medicare, and Congress

Reports out of Washington indicate Pres. Bush’s plans to expand HSAs by increasing the amount individuals can set aside tax-free are not gaining much traction on Capitol Hill. Sen. Chuck Grassley (R Nebraska) and other Republicans are not in favor of the move.
This is not Bush’s only problem related to health care. Some 60 House Republicans have refused to back the Bush Medicare budget cuts, breaking wiith the President despite calls for fiscal prudence. One wonders if election year politics has anything to do with this. Actually, there’s no wondering.
Republicans, faced with a President with historically low approval ratings (well, pretty close to historical lows) look to be scrambling for cover – and with seniors particularly upset with the GOP over the Part D mess, a cut to Medicare would increase their problems.
The situation on the Hill makes CMS Director McClellan’s recent pronouncements about adding HSAs to Medicare (Part G?!) somewhat…puzzling? Faced with concerns about both HSAs and Medicare among their own party leaders, why is McClellan floating this trial balloon? One can only imagine the reaction among seniors who have been tearing their hair out over Part D. If we thought Part D was complicated and hard to explain, I can’t wait to see our nation’s political leaders on a bus traveling around talking to seniors about HSAs.
What are these people thinking? Or rather, are these people thinking?
What does this mean for you?
Politics in an election year can be good and bad – killing the ill-conceived HSA expansion while not addressing some of the real concerns with Medicare are two great examples.


Mar
7

Copays, compliance, and costs

It will come as no surprise to most that a significant number of people do not take their medications as recommended. In fact, the number appears to be about 20%, at least according to a study funded by pharmaceutical company GlaxoSmithKline covering 429,000 Ohio health insurance claims for conditions such as diabetes, congestive heart failure and asthma. GSK’s study indicates that non-compliance adds over $700 million to the state’s health care costs.
Again not surprisingly, GSK has a plan to fix this problem. It involves eliminating copays for individuals if they agree to talk with a pharmacist at least once a month, and have the pharmacist check their blood sugar, pressure, and feet for sores. The extra payment to the pharmacist for their time, as well as the employees’ copays, will be funded by insurance companies or employers.
And last in this “dog bites man” story is the rather obvious note that although GSK et al will benefit by selling more drugs, they don’t appear to be contemplating any financial contribution to this noble cause.
What does this mean for you?
Two things.
One, another study that demonstrates the positive financial impact of reducing or removing copays for medications for chronic conditions. This has been documented previously, and calls into question what sems to be the main premise of the consumer-directed health plan – the theory that individuals will spend their money in such a way as to maximize their health.
Two, yet another example of big pharma shooting themselves in the foot. To look both smart and magnanimous, all GSK had to do was offer to partially fund the pharmacists’ extra time, provide the blood pressure monitors, reduce prices for insulin by $3 for those employers participating in the plan (either directly or through rebates) or otherwise do something altruistic. Instead, they fund a study (yay) that shows it makes sense for the rest of us to buy and use more drugs, thereby generating more revenue and profit for GSK et al.


Feb
22

PBM win over third party biller

For the dozen or so people in the workers comp business who follow these things, the recent win by ScripNet in its ongoing legal battle with third party biller (TPB) WorkingRx was excellent news – at least for the payers.. The court threw out WorkingRx’s lawsuit, noting that it had “no greater right to reimbursement from ScripNet than a pharmacy would have.”
WorkingRx and its competitor Third Party Solutions have been working two fronts in their effort to stabilize their businesses; suing payers who refuse to pay their bills in full, while attempting to sign deals with pharmacy benefit managers and payers in return for a “discount” off the TPB’s (inflated) charges.
The court win is by no means the final word; TPBs have proven to be remarkably resilient and are proof that businesses that can evolve quickly can survive.
What does this mean for you?
More clarity from the courts re the legal position of TPBs.


Feb
20

Repackagers’ margins

Physicians and clinics are finding that dispensing drugs to patients can be a very profitable venture. Advocates are claiming that the practice improves the quality of care and ensures the patient receives the necessary scripts.
Let’s take the quality of care issue first. No question – an obstacle to compliance is the requirement that the injured worker has to get the script filled. Therefore, the dispensing of meds by docs makes sense. The right drug gets into the patient’s hands quickly.
OK. That’s a good thing. But at what price?
An analysis by Alex Swedlow (data provided by Alex to me) et al at the California Workers Compensation Research Institute on 2004 data indicates the price for repackaged drugs is from two times higher than the fee schedule (for ibuprofen) to twelve times higher (generic Zantac). (CWCI will publish the full study in the near future)
And, repackaged drugs accounted for less than a third of all scripts, but over half of all dollars paid. This is especially troubling when one considers the overwhelming majority of the top 20 drugs are generic.
Sources indicate that the problem grew even worse last year, with some payers indicating a majority of scripts were for repackaged drugs.
What does this mean for you?
Higher costs for WC payers, businesses, and taxpayers in California.